Mini Review: Pulmonary Toxicity Secondary to Immunosuppressive Agents in the Treatment of Rheumatoid Arthritis.

doi:10.46940/sjomd.03.1010

Abstract

Rheumatoid arthritis (RA) is a chronic rheumatic disease, characterized by erosive and destructive arthritis, representing an important cause of disability. Interstitial lung disease is not a rare event and can be aggravated by several immunosuppressive medications. Methotrexate, once seen as a drug associated with interstitial pneumonitis, is now seen as an agent capable of slowing or preventing the progression of lung disease related to rheumatoid arthritis. Anti-TNFs currently represent the class with the greatest impact on the course of pulmonary disease in RA, with a significant increase in mortality. Among the immunobiological agents, abatacept and Rituximab stand out in relation to the pulmonary safety profile.

Highlights

Rheumatoid arthritis (RA) is a chronic rheumatic disease, of unknown etiology and essentially autoimmune in nature
The risk of RA-associated interstitial pneumonitis is higher in individuals with positive rheumatoid and / or anti-CCP factors, with frequent observation of asymptomatic patients with subclinical disease
Methotrexate, a drug considered the gold standard in the treatment of RA, has over time been implicated in the development of acute, subacute and chronic interstitial lung disease and in the progression of subclinical pulmonary fibrosis related to the underlying disease [3]

Summary

Introduction

Rheumatoid arthritis (RA) is a chronic rheumatic disease, of unknown etiology and essentially autoimmune in nature. It is characterized by chronic, erosive and destructive polyarthritis, affecting mainly small peripheral joints, representing an important cause of physical disability and disability [1]. The risk of RA-associated interstitial pneumonitis is higher in individuals with positive rheumatoid and / or anti-CCP factors, with frequent observation of asymptomatic patients with subclinical disease. It usually occurs in the first five years of the disease and it may precede joint involvement in up to 20% of cases. Interstitial lung disease stands out, notably the usual interstitial

Synthetic Disease Modifying Drugs

Biological Disease Modifying Drugs

Findings

Conclusion